The World Health Organization (WHO) has officially approved the first diagnostic test for mpox (previously known as monkeypox) under its Emergency Use Listing (EUL) protocol.
Developed by Abbott Molecular Inc., the Alinity m MPXV assay is poised to greatly improve the global diagnostic landscape, especially in countries grappling with ongoing mpox outbreaks.
This approval comes at a crucial moment, as over 30,000 suspected cases have emerged across Africa in 2024, with the Democratic Republic of the Congo, Burundi, and Nigeria reporting the highest numbers.
However, despite the surge in cases, testing capabilities in Africa remain severely constrained.
The Alinity m MPXV assay utilizes real-time PCR technology to identify monkeypox virus DNA from human skin lesion swabs, delivering quick and precise results.
Prompt diagnosis is essential for effective treatment, care, and control of the virus’s spread.
The WHO’s EUL process expedites the deployment of vital tools, including vaccines and diagnostic tests, in response to public health crises.
This emergency approval will remain in effect as long as the Public Health Emergency of International Concern (PHEIC) for mpox is declared.
Additionally, WHO is reviewing three more submissions and collaborating with manufacturers to expand diagnostic solutions……..original copy @thenews-chronicle.com